Senaste uppdateringen :
19/11/2024
cancerläkemedel   Gemcitabine hydrochloride  
injektion
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Accogem Mexiko
Antoril Argentina
Axigem Tyskland
Bendacitabin Tyskland
Binoptos Mexiko
Celzar Peru
Dercin Rumänien
Dhacibine Malaysia
Emcitab Colombia
Eriogem Argentina, Ecuador
Fotinex Argentina, Peru
Gebina Argentina
Gebitan Colombia
Gembio Argentina, Chile, Ecuador
Gemcimira Chile, Peru
Gemcit Portugal
Gemcitabin Tyskland
Gemcitac Chile
Gemko Turkiet
Gemsibin Turkiet
Gemsol Österrike
Gemtero Chile, Peru
Gemzar Australien, Belgien, Brasilien, Chile, Colombia, Danmark, Ecuador, Egypten, Finland, Förenade Arabemiraten, Förenta Staterna, Frankrike, Grekland, Iran, Irland, Island, Italien, Kanada, Kroatien, Luxemburg, Malaysia, Marocko, Mexiko, Nederländerna, Norge, nya Zeeland, Österrike, Polen, Portugal, Rumänien, Schweiz, Slovenien, Spanien, Storbritannien, Sverige, Sydafrikanska republiken, Thailand, Tunisien, Turkiet, Tyskland, Ungern, Venezuela
Gentabin Colombia
Haxanit Argentina, Peru
Lenfotabin Mexiko
Hänvisningar   injektion   Hänvisningar : Gemcitabine hydrochloride  
Typ Publikation
1422 tidningen Xu QA, Zhang Y, Trissel LA.
Physical and chemical stability of gemcitabine hydrochloride solutions.
J Am Pharm Assoc 1999 ; 39: 509-513.
1423 tidningen Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1501 tidningen Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Laboratorium Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1611 tidningen Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 tidningen Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 tidningen Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1663 tidningen Ponton JL, Munoz C, Rey M, Val M.
The stability of (lyophilized) gemcitabine in 0.9% sodium chloride injection.
EJHP 2002 ; 1: 23-25.
1925 tidningen Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 tidningen Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 tidningen Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2009 tidningen Trissel LA, Zhang Y.
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2262 tidningen Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2344 Laboratorium Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3262 tidningen Manners S, Galettis P, de Souza P.
Conditions causing gemcitabine crystallization.
J Oncol Pharm Practice 2011 ; 17, 4: 395-399.
3496 Laboratorium Gemcitabin Actavis solution - Stability Study
Actavis 2009
3670 tidningen Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
4310 tidningen Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.
4736 tidningen Closset M, Colsoul ML, Goderniaux N, Bihin B, Jamart J, Onorati S, Soumoy L, Hecq JD, Odou P, Galanti L.
An Ultra-High-Performance Chromatography method to study the long term stability of gemcitabine in dose banding conditions.
J Pharm Biomed Anal 2023

  Mentions Légales